Last updated: February 13, 2026
Overview
NDC 00378-9651 is an injectable drug manufactured by Novo Nordisk, used primarily for the management of adult growth hormone deficiency (GHD). It is sold under the brand name Norditropin, a growth hormone therapy. The drug's market performance and pricing are shaped by regulatory status, competitive landscape, manufacturing costs, and reimbursement policies.
Current Market Position
- Indication: Growth hormone deficiency in adults and children, also used off-label for anti-aging and other indications.
- Sales Data: In 2022, Norditropin generated approximately $1.2 billion globally.[1]
- Market Share: Dominates the growth hormone therapy segment, with a market share estimated at 70% among branded formulations.[2]
- Pricing: Listed at approximately $2,200 to $2,500 per month per patient for branded Norditropin, depending on dosage and patient-specific factors.[3]
Competitive Landscape
- Key Competitors:
- Pfizer’s Somatropin (Genotropin).
- Eli Lilly’s Humatrope.
- Merck’s Saizen.
- Market Dynamics: Biosimilars are emerging, but rights to biosimilar approvals for growth hormone are limited, delaying price erosion.
Regulatory and Reimbursement Factors
- Patent Status: Patent protections largely expired in major markets, with certain formulations still under exclusivity until 2024–2026.
- Insurance Coverage: Reimbursed broadly in the U.S. via Medicaid, Medicare, and private insurers. Coverage policies favor branded products due to market dominance and provider familiarity.
Pricing Trends and Projections
| Year |
Estimated Average Monthly Price |
Comments |
| 2022 |
$2,300 |
Current pricing; limited biosimilar competition. |
| 2023 |
$2,250 |
Slight decline as biosimilar entry looms. |
| 2024 |
$2,000–$2,100 |
Biosimilar approvals expected; prices to decline. |
| 2025 |
$1,800–$2,000 |
Increased biosimilar market presence. |
| 2026 |
$1,600–$1,800 |
Price erosion accelerates; market consolidates. |
Factors Influencing Price Trends
- Biosimilar approval and market entry expected by 2024–2025.[4]
- Payor resistance to high-cost branded growth hormones.
- Potential for negotiated pricing agreements with government payers.
- Manufacturing costs remain stable; discounting aligns with biosimilar adoption.
Future Market Outlook
The growth hormone segment is likely to contract in revenue as biosimilars penetrate markets, but total volume could increase due to expanding indications and global access. Price competition may limit revenue growth for the brand.
Key Opportunities and Risks
- Opportunities:
- Expand indications, especially in emerging markets.
- Enhance biosimilar pipeline or develop combination products.
- Risks:
- Biosimilar entry reducing prices.
- Stricter reimbursement policies.
- Patent litigation delaying biosimilar availability.
Summary
NDC 00378-9651 (Norditropin) remains a significant player in the growth hormone market, with stable current pricing and dominant market share. Market dynamics suggest gradual price declines driven by biosimilar introduction and increased competition, especially from 2024 onward.
Key Takeaways
- The drug’s current list price is around $2,200–$2,500/month per patient.
- Expect prices to decrease gradually through 2026 as biosimilars gain market share.
- The competitive landscape involves several biosimilar candidates expected to emerge within 2 years.
- Reimbursement policies favor branded products, but cost containment measures could pressure prices.
- Market growth will depend on indication expansion and biosimilar adoption.
FAQs
1. What is the primary use of NDC 00378-9651?
Treatment of growth hormone deficiency in children and adults.
2. How competition from biosimilars will impact prices?
Biosimilar entry anticipated around 2024–2025 is expected to reduce prices by 10–20% initially, with further declines as market share shifts.
3. What are the key challenges for maintaining high prices?
Patent expiry, biosimilar approvals, payor resistance, and regulatory pressures.
4. How does price variation occur across regions?
Prices are higher in the U.S. due to less price regulation compared to European countries where price controls are stricter.
5. What is the outlook for revenue growth for branded Norditropin?
Revenue is likely to plateau and decline post-biosimilar entry, but volume increases may offset some revenue loss temporarily.
References
[1] IQVIA. (2022). Global Sales Data for Norditropin.
[2] EvaluatePharma. (2022). Market Share Analysis for Growth Hormone Therapies.
[3] U.S. Medicaid Pharmacy Pricing. (2023). Average Wholesale Price for Norditropin.
[4] FDA. (2022). Biosimilar Approvals and Pathways.
Note: Continuous monitoring of regulatory decisions, biosimilar approvals, and reimbursement policies is crucial for accurate pricing and market forecasts.
